menu search

DARE / Daré Bioscience's 'female Viagra' could be first-in-category product: broker

Daré Bioscience's 'female Viagra' could be first-in-category product: broker
Daré Bioscience could have a first-in-category product on its hands with its “female Viagra” offering, analysts at Dawson James believe. The women's health-focused biopharmaceutical company on Tuesday reported positive results from its Phase 2b RESPOND study evaluating its proprietary topical formulation of sildenafil (sildenafil cream 3.6%) as a treatment for female sexual arousal disorder (FSAD), a condition for which there is no Food and Drug Administration (FDA)-approved treatment. Read More
Posted: Jul 13 2023, 16:26
Author Name: Proactive Investors
Views: 112561

DARE News  

Daré Bioscience's 'female Viagra' could be first-in-category product: broker

By Proactive Investors
July 13, 2023

Daré Bioscience's 'female Viagra' could be first-in-category product: broker

Daré Bioscience could have a first-in-category product on its hands with its “female Viagra” offering, analysts at Dawson James believe. The wome more_horizontal

Daré Bioscience, Inc. (DARE) Q1 2023 Earnings Call Transcript

By Seeking Alpha
May 11, 2023

Daré Bioscience, Inc. (DARE) Q1 2023 Earnings Call Transcript

Daré Bioscience, Inc. (NASDAQ:DARE ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Sabrina Martucci Johnson – Presi more_horizontal

Dare Bioscience, Inc. (DARE) Q4 2022 Earnings Call Transcript

By Seeking Alpha
March 30, 2023

Dare Bioscience, Inc. (DARE) Q4 2022 Earnings Call Transcript

Dare Bioscience, Inc. (NASDAQ:DARE ) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Sabrina Johnson - President & Chi more_horizontal

Dare Bioscience, Inc. (DARE) Upgraded to Buy: What Does It Mean for the Stock?

By Zacks Investment Research
November 15, 2022

Dare Bioscience, Inc. (DARE) Upgraded to Buy: What Does It Mean for the Stock?

Dare Bioscience, Inc. (DARE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This migh more_horizontal

Dare Bioscience, Inc. (DARE) Q3 2022 Earnings Call Transcript

By Seeking Alpha
November 10, 2022

Dare Bioscience, Inc. (DARE) Q3 2022 Earnings Call Transcript

Dare Bioscience, Inc. (NASDAQ:DARE ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Sabrina Johnson - President an more_horizontal

Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates

By Zacks Investment Research
November 10, 2022

Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Misses Revenue Estimates

Dare Bioscience, Inc. (DARE) delivered earnings and revenue surprises of 27.27% and 100%, respectively, for the quarter ended September 2022. Do the n more_horizontal

Dare Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q1 2022 Results - Earnings Call Transcript

By Seeking Alpha
May 12, 2022

Dare Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q1 2022 Results - Earnings Call Transcript

Dare Bioscience, Inc. (NASDAQ:DARE ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Sabrina Martucci Johnson - Presiden more_horizontal

Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q4 2021 Results - Earnings Call Transcript

By Seeking Alpha
March 31, 2022

Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q4 2021 Results - Earnings Call Transcript

Daré Bioscience, Inc. (DARE) CEO Sabrina Martucci Johnson on Q4 2021 Results - Earnings Call Transcript more_horizontal


Search within

Pages Search Results: